Cite
Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning.
MLA
Pol, Jonathan G., et al. “Enhanced Immunotherapeutic Profile of Oncolytic Virus-Based Cancer Vaccination Using Cyclophosphamide Preconditioning.” Journal for Immunotherapy of Cancer, vol. 8, no. 2, Aug. 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-000981.
APA
Pol, J. G., Atherton, M. J., Stephenson, K. B., Bridle, B. W., Workenhe, S. T., Kazdhan, N., McGray, A. R., Wan, Y., Kroemer, G., & Lichty, B. D. (2020). Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-000981
Chicago
Pol, Jonathan G, Matthew J Atherton, Kyle B Stephenson, Byram W Bridle, Samuel T Workenhe, Natasha Kazdhan, Aj Robert McGray, Yonghong Wan, Guido Kroemer, and Brian D Lichty. 2020. “Enhanced Immunotherapeutic Profile of Oncolytic Virus-Based Cancer Vaccination Using Cyclophosphamide Preconditioning.” Journal for Immunotherapy of Cancer 8 (2). doi:10.1136/jitc-2020-000981.